ProAssurance downgraded to Underperform from Market Perform at Raymond James

Raymond James downgraded ProAssurance (PRA) to Underperform from Market Perform without a price target The firm sees limited upside in the stock price over the next 12 months while the acquisition by The Doctors Co. is pending regulatory approval. ProAssurance trades at a higher multiple than peers with a lower 2025 estimated return on equity, the analyst tells investors in a research note. Raymond James’ regression analysis suggests more potential upside with other names in its coverage, especially considering the recent market volatility.